First European patient enrolled in Medtronic DBS therapy registry; Teleflex taps Powell as new CFO;

@FierceMedDev: NY Times: Asahi Kasei of Japan Agrees to Buy Zoll Medical for $2.2 Billion. News | Follow @FierceMedDev

> The first subject has been enrolled in the MORE registry in Europe to investigate Medtronic ($MDT) deep brain stimulation therapy in patients with refractory epilepsy. DBS for epilepsy received CE Mark in August 2010. Medtronic release

> Teleflex ($TFX) has named Thomas Powell, who joined the company last year, as senior VP and CFO. He replaces Richard Meier, whose employment with the company was terminated earlier this month. Teleflex release

> Qiagen is looking to boost HPV screening in China through a co-marketing agreement with KingMed Diagnostics. Qiagen release

> Zynex has wrapped up its previously announced acquisition of NeuroDyne Medical. Zynex release

> With imaging serving as one of the key drivers of increased healthcare costs, evidence-based strategies to reduce variation in head CT use could reduce costs and improve care quality, according to a new Harvard Medical School/Brigham & Women's Hospital study. Release

> New Zealand researchers have developed a prototype Bluetooth-enabled monitoring device that can be connected wirelessly to a smartphone. It can monitor such things as body temperature, heart rate, blood pressure and movements. The researchers hope to expand its capabilities. Release

And Finally... The Nintendo Wii has been touted as an exercise center and dance studio--among other things. Now the Wii Remote is being used as a medical device to diagnose ocular torticollis, an eye condition. Report

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.